32 articles for B De
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
Procter and Gamble Pharmaceuticals
Synthesis and In Vitro evaluation of fused ring heterocyle-containing angiotensin II antagonists.
TBA
Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
Procter and Gamble Pharmaceuticals
Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3.
Procter and Gamble Pharmaceuticals
Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
Procter and Gamble Pharmaceuticals
Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1beta synthesis.
Procter & Gamble Pharmaceuticals
Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.
TBA
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
Procter and Gamble Pharmaceuticals
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Procter and Gamble Pharmaceuticals
Discovery of potent, achiral matrix metalloproteinase inhibitors.
Procter and Gamble Pharmaceuticals
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
Abbott Laboratories
Heterocycle-based MMP inhibitors with P2' substituents.
Procter and Gamble Pharmaceuticals
Synthesis and evaluation of unsaturated caprolactams as interleukin-1beta converting enzyme (ICE) inhibitors.
Procter & Gamble Pharmaceuticals
The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Procter and Gamble Pharmaceuticals
Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1beta converting enzyme (ICE) inhibitors.
Procter & Gamble Pharmaceuticals
The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Procter and Gamble Pharmaceuticals
Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
Procter & Gamble Pharmaceuticals
Synthesis and evaluation of novel 8,6-fused bicyclic peptidomimetic compounds as interleukin-1beta converting enzyme inhibitors.
Procter & Gamble Pharmaceuticals
The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
Procter and Gamble Pharmaceuticals
The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.
Procter and Gamble Pharmaceuticals
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
Procter & Gamble Pharmaceuticals
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.
Procter and Gamble Pharmaceuticals
Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.
Procter and Gamble Pharmaceuticals
Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.
Procter and Gamble Pharmaceuticals
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
Procter and Gamble Pharmaceuticals
Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.
Procter and Gamble Pharmaceuticals
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.
University of Florida
Design and synthesis of conformationally-constrained MMP inhibitors.
Procter and Gamble Pharmaceuticals
The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.
Procter and Gamble Pharmaceuticals
Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.
Procter and Gamble Pharmaceuticals
LH-RH antagonists: design and synthesis of a novel series of peptidomimetics.
Abbott Laboratories